Glucagon-like peptide 1 receptor agonists as a potential way to overcome treatment resistance in psoriasis and psoriatic arthritis
Abstract
Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are characterized by a high prevalence of concomitant obesity and metabolic disorders, and an increased body mass index (BMI) increases the likelihood of PsA development in patients with PsO. Obesity, as well as PsO/PsA, is associated with increased cardiovascular risk and reduced quality of life. Achieving minimal disease activity in PsO/PsA in obese patients may be challenging. Effective and sustained BMI reduction (regardless of the method) increases the likelihood of achieving remission and enhances the efficacy of tumor necrosis factor α (TNFα) inhibitors.This review presents the results of studies on the effects of the most commonly used drug class for obesity treatment — glucagon-like peptide 1 receptor agonists — on PsO/PsA activity, as well as their combined use with biologic agents.
Fields of Study & Subjects
Diabetes Treatment and Management
Psoriasis: Treatment and Pathogenesis
Adenosine and Purinergic Signaling
Publication details
- Journal / source
- Modern Rheumatology Journal
- Publisher
- IMA Press, LLC
- Volume
- 20
- Issue
- 3
- Pages
- 84–90
- Publication date
- 24 June 2026
- Language
- RU